Skip to main content
Erschienen in: Journal of Genetic Counseling 3/2017

20.08.2016 | Original Research

Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age

verfasst von: Joann Seo, Jennifer Ivanovich, Melody S. Goodman, Barbara B. Biesecker, Kimberly A. Kaphingst

Erschienen in: Journal of Genetic Counseling | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

We investigated what information women diagnosed with breast cancer at a young age would want to learn when genome sequencing results are returned. We conducted 60 semi-structured interviews with women diagnosed with breast cancer at age 40 or younger. We examined what specific information participants would want to learn across result types and for each type of result, as well as how much information they would want. Genome sequencing was not offered to participants as part of the study. Two coders independently coded interview transcripts; analysis was conducted using NVivo10. Across result types, participants wanted to learn about health implications, risk and prevalence in quantitative terms, causes of variants, and causes of diseases. Participants wanted to learn actionable information for variants affecting risk of preventable or treatable disease, medication response, and carrier status. The amount of desired information differed for variants affecting risk of unpreventable or untreatable disease, with uncertain significance, and not health-related. Women diagnosed with breast cancer at a young age recognize the value of genome sequencing results in identifying potential causes and effective treatments and expressed interest in using the information to help relatives and to further understand their other health risks. Our findings can inform the development of effective feedback strategies for genome sequencing that meet patients’ information needs and preferences.
Literatur
Zurück zum Zitat Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. doi:10.1200/jco.2007.14.2471.CrossRefPubMed Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. doi:10.​1200/​jco.​2007.​14.​2471.CrossRefPubMed
Zurück zum Zitat Bonadona, V., Sinilnikova, O. M., Chopin, S., Antoniou, A. C., Mignotte, H., Mathevet, P., et al. (2005). Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes, Chromosomes & Cancer, 43(4), 404–413. doi:10.1002/gcc.20199.CrossRef Bonadona, V., Sinilnikova, O. M., Chopin, S., Antoniou, A. C., Mignotte, H., Mathevet, P., et al. (2005). Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes, Chromosomes & Cancer, 43(4), 404–413. doi:10.​1002/​gcc.​20199.CrossRef
Zurück zum Zitat Christenhusz, G. M., Devriendt, K., Peeters, H., Van Esch, H., & Dierickx, K. (2014). The communication of secondary variants: interviews with parents whose children have undergone array-CGH testing. Clinical Genetics, 86(3), 207–216. doi:10.1111/cge.12354.CrossRefPubMed Christenhusz, G. M., Devriendt, K., Peeters, H., Van Esch, H., & Dierickx, K. (2014). The communication of secondary variants: interviews with parents whose children have undergone array-CGH testing. Clinical Genetics, 86(3), 207–216. doi:10.​1111/​cge.​12354.CrossRefPubMed
Zurück zum Zitat Crouch, J., Yu, J. H., Shankar, A. G., & Tabor, H. K. (2015). “We don’t know her history, her background”: adoptive parents’ perspectives on whole genome sequencing results. Journal of Genetic Counseling, 24(1), 67–77. doi:10.1007/s10897-014-9738-z.CrossRefPubMed Crouch, J., Yu, J. H., Shankar, A. G., & Tabor, H. K. (2015). “We don’t know her history, her background”: adoptive parents’ perspectives on whole genome sequencing results. Journal of Genetic Counseling, 24(1), 67–77. doi:10.​1007/​s10897-014-9738-z.CrossRefPubMed
Zurück zum Zitat Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747–3752. doi:10.1200/jco.2010.34.0778.CrossRefPubMed Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747–3752. doi:10.​1200/​jco.​2010.​34.​0778.CrossRefPubMed
Zurück zum Zitat Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951. doi:10.1001/jamaoncol.2015.2690.CrossRefPubMed Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951. doi:10.​1001/​jamaoncol.​2015.​2690.CrossRefPubMed
Zurück zum Zitat Dressler, L. G. (2009a). Biobanking and disclosure of research results: Addressing the tension between professional boundaries and moral intuition. In J. H. Solbakk, S. Holm, & B. Hofmann (Eds.), The ethics of research biobanking (pp. 85–99). New York: Springer.CrossRef Dressler, L. G. (2009a). Biobanking and disclosure of research results: Addressing the tension between professional boundaries and moral intuition. In J. H. Solbakk, S. Holm, & B. Hofmann (Eds.), The ethics of research biobanking (pp. 85–99). New York: Springer.CrossRef
Zurück zum Zitat Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., & Mardis, E. R. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353–360. doi:10.1038/nature11143.PubMedPubMedCentral Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., & Mardis, E. R. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353–360. doi:10.​1038/​nature11143.PubMedPubMedCentral
Zurück zum Zitat Facio, F. M., Brooks, S., Loewenstein, J., Green, S., Biesecker, L. G., & Biesecker, B. B. (2011). Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. European Journal of Human Genetics, 19(12), 1213–1217. doi:10.1038/ejhg.2011.123.CrossRefPubMedPubMedCentral Facio, F. M., Brooks, S., Loewenstein, J., Green, S., Biesecker, L. G., & Biesecker, B. B. (2011). Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. European Journal of Human Genetics, 19(12), 1213–1217. doi:10.​1038/​ejhg.​2011.​123.CrossRefPubMedPubMedCentral
Zurück zum Zitat Golshan, M., Miron, A., Nixon, A. J., Garber, J. E., Cash, E. P., Iglehart, J. D., & Wong, J. S. (2006). The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. American Journal of Surgery, 192(1), 58–62. doi:10.1016/j.amjsurg.2005.12.005.CrossRefPubMed Golshan, M., Miron, A., Nixon, A. J., Garber, J. E., Cash, E. P., Iglehart, J. D., & Wong, J. S. (2006). The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. American Journal of Surgery, 192(1), 58–62. doi:10.​1016/​j.​amjsurg.​2005.​12.​005.CrossRefPubMed
Zurück zum Zitat Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Genomics (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574. doi:10.1038/gim.2013.73.CrossRefPubMedPubMedCentral Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Genomics (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574. doi:10.​1038/​gim.​2013.​73.CrossRefPubMedPubMedCentral
Zurück zum Zitat Guba, E. G., & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. In N. K. Denzin & Y. S. Lincoln (Eds.), Handbook of qualitative research (pp. 105–117). Thousand Oaks: Sage. Guba, E. G., & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. In N. K. Denzin & Y. S. Lincoln (Eds.), Handbook of qualitative research (pp. 105–117). Thousand Oaks: Sage.
Zurück zum Zitat Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et al. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International Journal of Cancer, 136(3), 668–677. doi:10.1002/ijc.29032.PubMed Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et al. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International Journal of Cancer, 136(3), 668–677. doi:10.​1002/​ijc.​29032.PubMed
Zurück zum Zitat Ingham, S. L., Sperrin, M., Baildam, A., Ross, G. L., Clayton, R., Lalloo, F., et al. (2013). Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 142(3), 611–618. doi:10.1007/s10549-013-2765-x.CrossRefPubMed Ingham, S. L., Sperrin, M., Baildam, A., Ross, G. L., Clayton, R., Lalloo, F., et al. (2013). Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 142(3), 611–618. doi:10.​1007/​s10549-013-2765-x.CrossRefPubMed
Zurück zum Zitat Institute of Medicine (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, D.C.: National Academies Press. Institute of Medicine (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, D.C.: National Academies Press.
Zurück zum Zitat Jamal, S. M., Yu, J. H., Chong, J. X., Dent, K. M., Conta, J. H., Tabor, H. K., & Bamshad, M. J. (2013). Practices and policies of clinical exome sequencing providers: analysis and implications. American Journal of Medical Genetics. Part A, 161A(5), 935–950. doi:10.1002/ajmg.a.35942.CrossRefPubMed Jamal, S. M., Yu, J. H., Chong, J. X., Dent, K. M., Conta, J. H., Tabor, H. K., & Bamshad, M. J. (2013). Practices and policies of clinical exome sequencing providers: analysis and implications. American Journal of Medical Genetics. Part A, 161A(5), 935–950. doi:10.​1002/​ajmg.​a.​35942.CrossRefPubMed
Zurück zum Zitat Janatova, M., Kleibl, Z., Stribrna, J., Panczak, A., Vesela, K., Zimovjanova, M., et al. (2013). The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 22(12), 2323–2332. doi:10.1158/1055-9965.epi-13-0745-t.CrossRef Janatova, M., Kleibl, Z., Stribrna, J., Panczak, A., Vesela, K., Zimovjanova, M., et al. (2013). The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 22(12), 2323–2332. doi:10.​1158/​1055-9965.​epi-13-0745-t.CrossRef
Zurück zum Zitat Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Brody, L. C., & Baxevanis, A. D. (2010). Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. Journal of Medical Internet Research, 12(3), e41. doi:10.2196/jmir.1587.CrossRefPubMedPubMedCentral Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Brody, L. C., & Baxevanis, A. D. (2010). Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. Journal of Medical Internet Research, 12(3), e41. doi:10.​2196/​jmir.​1587.CrossRefPubMedPubMedCentral
Zurück zum Zitat Kaphingst, K. A., Ivanovich, J., Biesecker, B. B., Dresser, R., Seo, J., Dressler, L. G., & Goodman, M. S. (2016). Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young Age. Clinical Genetics, 89(3), 378–384. doi:10.1111/cge.12597.CrossRefPubMed Kaphingst, K. A., Ivanovich, J., Biesecker, B. B., Dresser, R., Seo, J., Dressler, L. G., & Goodman, M. S. (2016). Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young Age. Clinical Genetics, 89(3), 378–384. doi:10.​1111/​cge.​12597.CrossRefPubMed
Zurück zum Zitat Leventhal, K. G., Tuong, W., Peshkin, B. N., Salehizadeh, Y., Fishman, M. B., Eggly, S., et al. (2013). “Is it really worth it to get tested?”: primary care patients’ impressions of predictive SNP testing for colon cancer. Journal of Genetic Counseling, 22(1), 138–151. doi:10.1007/s10897-012-9530-x.CrossRefPubMed Leventhal, K. G., Tuong, W., Peshkin, B. N., Salehizadeh, Y., Fishman, M. B., Eggly, S., et al. (2013). “Is it really worth it to get tested?”: primary care patients’ impressions of predictive SNP testing for colon cancer. Journal of Genetic Counseling, 22(1), 138–151. doi:10.​1007/​s10897-012-9530-x.CrossRefPubMed
Zurück zum Zitat Matsui, K., Lie, R. K., Kita, Y., & Ueshima, H. (2008). Ethics of future disclosure of individual risk information in a genetic cohort study: a survey of donor preferences. Journal of Epidemiology, 18(5), 217–224.CrossRefPubMedPubMedCentral Matsui, K., Lie, R. K., Kita, Y., & Ueshima, H. (2008). Ethics of future disclosure of individual risk information in a genetic cohort study: a survey of donor preferences. Journal of Epidemiology, 18(5), 217–224.CrossRefPubMedPubMedCentral
Zurück zum Zitat Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812–822. doi:10.1093/jnci/djt095.CrossRefPubMed Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812–822. doi:10.​1093/​jnci/​djt095.CrossRefPubMed
Zurück zum Zitat Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., et al. (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 38(8), 873–875. doi:10.1038/ng1837.CrossRefPubMed Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., et al. (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 38(8), 873–875. doi:10.​1038/​ng1837.CrossRefPubMed
Zurück zum Zitat Riedl, C. C., Slobod, E., Jochelson, M., Morrow, M., Goldman, D. A., Gonen, M., & Ulaner, G. A. (2014). Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. Journal of Nuclear Medicine, 55(10), 1578–1583. doi:10.2967/jnumed.114.143297.CrossRefPubMedPubMedCentral Riedl, C. C., Slobod, E., Jochelson, M., Morrow, M., Goldman, D. A., Gonen, M., & Ulaner, G. A. (2014). Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. Journal of Nuclear Medicine, 55(10), 1578–1583. doi:10.​2967/​jnumed.​114.​143297.CrossRefPubMedPubMedCentral
Zurück zum Zitat Rutten, L. J., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Education and Counseling, 57(3), 250–261. doi:10.1016/j.pec.2004.06.006.CrossRefPubMed Rutten, L. J., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Education and Counseling, 57(3), 250–261. doi:10.​1016/​j.​pec.​2004.​06.​006.CrossRefPubMed
Zurück zum Zitat Schmidlen, T. J., Wawak, L., Kasper, R., Garcia-Espana, J. F., Christman, M. F., & Gordon, E. S. (2014). Personalized genomic results: analysis of informational needs. Journal of Genetic Counseling, 23(4), 578–587. doi:10.1007/s10897-014-9693-8.CrossRefPubMed Schmidlen, T. J., Wawak, L., Kasper, R., Garcia-Espana, J. F., Christman, M. F., & Gordon, E. S. (2014). Personalized genomic results: analysis of informational needs. Journal of Genetic Counseling, 23(4), 578–587. doi:10.​1007/​s10897-014-9693-8.CrossRefPubMed
Zurück zum Zitat Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225. doi:10.1089/gtmb.2012.0165.CrossRefPubMed Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225. doi:10.​1089/​gtmb.​2012.​0165.CrossRefPubMed
Zurück zum Zitat Sieh, W., Rothstein, J. H., McGuire, V., & Whittemore, A. S. (2014). The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2322–2327. doi:10.1158/1055-9965.epi-14-0559.CrossRef Sieh, W., Rothstein, J. H., McGuire, V., & Whittemore, A. S. (2014). The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2322–2327. doi:10.​1158/​1055-9965.​epi-14-0559.CrossRef
Zurück zum Zitat Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J. H., et al. (2012). Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics. Part A, 158A(6), 1310–1319. doi:10.1002/ajmg.a.35328.CrossRefPubMedPubMedCentral Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J. H., et al. (2012). Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics. Part A, 158A(6), 1310–1319. doi:10.​1002/​ajmg.​a.​35328.CrossRefPubMedPubMedCentral
Zurück zum Zitat Taplin, S. H., Anhang Price, R., Edwards, H. M., Foster, M. K., Breslau, E. S., Chollette, V., et al. (2012). Introduction: Understanding and influencing multilevel factors across the cancer care continuum. Journal of the National Cancer Institute. Monographs, 2012(44), 2–10. doi:10.1093/jncimonographs/lgs008.CrossRefPubMedPubMedCentral Taplin, S. H., Anhang Price, R., Edwards, H. M., Foster, M. K., Breslau, E. S., Chollette, V., et al. (2012). Introduction: Understanding and influencing multilevel factors across the cancer care continuum. Journal of the National Cancer Institute. Monographs, 2012(44), 2–10. doi:10.​1093/​jncimonographs/​lgs008.CrossRefPubMedPubMedCentral
Zurück zum Zitat Trujillano, D., Weiss, M. E., Schneider, J., Koster, J., Papachristos, E. B., Saviouk, V., et al. (2015). Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. The Journal of Molecular Diagnostics, 17(2), 162–170. doi:10.1016/j.jmoldx.2014.11.004.CrossRefPubMed Trujillano, D., Weiss, M. E., Schneider, J., Koster, J., Papachristos, E. B., Saviouk, V., et al. (2015). Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. The Journal of Molecular Diagnostics, 17(2), 162–170. doi:10.​1016/​j.​jmoldx.​2014.​11.​004.CrossRefPubMed
Zurück zum Zitat Wright, M. F., Lewis, K. L., Fisher, T. C., Hooker, G. W., Emanuel, T. E., Biesecker, L. G., & Biesecker, B. B. (2014). Preferences for results delivery from exome sequencing/genome sequencing. Genetics in Medicine, 16(6), 442–447. doi:10.1038/gim.2013.170.CrossRefPubMed Wright, M. F., Lewis, K. L., Fisher, T. C., Hooker, G. W., Emanuel, T. E., Biesecker, L. G., & Biesecker, B. B. (2014). Preferences for results delivery from exome sequencing/genome sequencing. Genetics in Medicine, 16(6), 442–447. doi:10.​1038/​gim.​2013.​170.CrossRefPubMed
Zurück zum Zitat Yu, J. H., Crouch, J., Jamal, S. M., Bamshad, M. J., & Tabor, H. K. (2014). Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing. American Journal of Medical Genetics. Part A, 164A(9), 2153–2160. doi:10.1002/ajmg.a.36610.CrossRefPubMed Yu, J. H., Crouch, J., Jamal, S. M., Bamshad, M. J., & Tabor, H. K. (2014). Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing. American Journal of Medical Genetics. Part A, 164A(9), 2153–2160. doi:10.​1002/​ajmg.​a.​36610.CrossRefPubMed
Metadaten
Titel
Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age
verfasst von
Joann Seo
Jennifer Ivanovich
Melody S. Goodman
Barbara B. Biesecker
Kimberly A. Kaphingst
Publikationsdatum
20.08.2016
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 3/2017
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-016-0006-2

Weitere Artikel der Ausgabe 3/2017

Journal of Genetic Counseling 3/2017 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.